Non-alcoholic fatty liver disease (NAFLD) is a complication of global prevalence occurring due to defective regulation of hepatic lipid metabolism. Currently, NAFLD is being viewed as an emerging epidemic by virtue of increase in obesity cases. Accumulation of excess fatty acid in the liver, leads to activation of an array of inflammatory signals, resulting in hepatic steatosis. Inadequately tr...

AIM To identify a panel of biomarkers that can distinguish between non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and explore molecular mechanism involved in the process of developing NASH from NAFLD. METHODS Biomarkers may differ during stages of NAFLD. Urine and blood were obtained from non-diabetic subjects with NAFLD and steatosis, with normal liver fu...

conclusions elevated serum pth level was the predictive factor for nash in morbidly obese patients. also, we reported elevated serum liver enzymes, high serum pth levels and older age as predictors of nash in patients seeking obesity surgical treatments. results forty-six patients (34 women, aged 36.5 ± 10.6 years) were analyzed. the mean levels of liver enzymes were significantly higher in the...

Introduction and objective. The deficiency of the Lysosomal acid lipase (LAL) activity has been related to cirrhosis due non-alcoholic steatohepatitis (NASH). Many classified as cryptogenic are evolution liver disease fatty liver. objective present study was evaluate lysosomal in patients with any etiology establish whether low levels correlate origin or NASH. Methods. Was an analytical cohort ...

PURPOSE To determine the prevalence of non alcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery and to identify risk factors associated with the disease spectrum. METHODS Liver biopsy was performed in 60 patients who underwent bariatric surgery, after other causes of liver disease were excluded. Clinical, bioche...

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of a metabolic syndrome. To date, liver biopsy has been the gold standard used to differentiate between simple steatosis and steatohepatitis/fibrosis. Our aim was to compare the relevance of serum non-invasive parameters and scoring systems in the staging of liver fibrosis and non-alcoholic steatohepatitis (NASH) ...

While non-alcoholic fatty liver disease (NAFLD) is highly prevalent (15% to 45%) in modern societies, only 10% to 25% of cases develop hepatic fibrosis leading to cirrhosis, end-stage liver disease or hepatocellular carcinoma. Apart from pre-existing fibrosis, the strongest predictor of fibrotic progression in NAFLD is steatohepatitis or non-alcoholic steatohepatitis (NASH). The critical featur...

Non-alcoholic fatty liver disease (NAFLD) is emerging as a common medical problem. Nonalcoholic steatohepatitis (NASH) is the critical turning point at which NAFLD progresses to more advanced stages such as hepatic fibrosis, cirrhosis and even hepatocellular carcinoma. However, the study of the pathogenic or therapeutic factors involved in NASH has been hampered by the absence of a suitable exp...

OBJECTIVE Angiotensin II, one component of renin-angiotensin system (RAS), is formed from Ang I by the catalysing of angiotensin converting enzyme (ACE). Angiotensin II plays an important role in the development of insulin resistance. ACE2, a homologue of ACE, couterregulate the actions of angiotensin II by facilitating its breakdown to angiotensin-(1-7). RAS has been implicated in the pathogen...

Gut microbiota plays a significant role in the development of hepatocellular carcinoma (HCC) in non-alcoholic steatohepatitis (NASH). However, understanding of the precise mechanism of this process remains incomplete. A new class steatohepatitis-inducing high-fat diet (HFD), namely STHD-01, can promote the development of HCC without the administration of chemical carcinogens. Using this diet, w...